

Dementia Management Act and Death Toll by Dementia Drug

Jong-hoon Lee (✉ science@research.re.kr)

Seoul National University College of Medicine <https://orcid.org/0000-0003-1775-5656>

Article

Keywords: Dementia Management Act (DMA), Alzheimer's disease (AD), anti-AD drug (AAD) groups, death toll

Posted Date: April 29th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-384861/v3>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

The Dementia Management Act (DMA) came into effect on August 4, 2011, in South Korea. Medical data on the correlation between Alzheimer's disease (AD) and anti-AD drug (AAD) groups were observed from 2010 to 2019. This study investigated the increase and decrease in deaths and AAD used to treat AD. It is known that psychotropic medicines should not be administered for dementia patients because they increase all-cause mortality. This study demonstrated that acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists increase the death toll when used to treat dementia.

Introduction

National data about mortality in people with specific disabilities provides a basis for public health interventions. Life expectancy is data accumulated over decades. Linked mortality data using medical records to identify people with specific disabilities like leprosy and intellectual disabilities could provide comprehensive unbiased population-based monitoring in spite of the circumstances of illnesses or death^{1 2}.

According to the Dementia Management Act (DMA), the Sorokdo National Hospital, established to treat leprosy in May of 1916, has provided Alzheimer's disease (AD) treatment and preventive services for Hansen's disease (HD) patients. There were HD patients who just settled in 2020 to those who had lived most of life for 79 years in Sorok Island. The decrease or increase of life expectancy of HD patients is fundamental data^{3 4 5}. The life expectancy of HD Patient in South Korea is known to live longer than life expectancy of Koreans⁶. Some studies lead our understanding for HD patients' longevity to the effects of dapsone (4,4'-Diaminodiphenyl Sulfone, DDS) which is one of multi drug treatment therapy for leprosy^{7 8 9 10}. It should be very peculiar, but it needs to be examined thoroughly.

The DMA's purpose is to mitigate personal pain and damage from dementia. The DMA came into effect on August 04, 2011, in South Korea, and it was amended on June 12, 2018¹¹. Medical personnel, psychiatrists, or neurologists of medical institutions and workers engaged in providing medical services under the Medical Service Act became very active in the dementia management programmes being executed by the state and local governments. According to the DMA policy, AD patients and AAD prescriptions are increasing rapidly, so it is most necessary to analyse national medical data. AAD group 1 is dementia symptom treatments: donepezil hydrochloride, rivastigmine, galantamine, and NMDA receptor antagonists. AAD group 2 includes psychotropic medications such as haloperidol, risperidone, quetiapine, olanzapine, aripiprazole, oxcarbazepine, fluvoxamine, escitalopram, trazodone, sertraline, and fluoxetine.

South Korea's electronic data interchange (EDI) medical procedure code is well-computerised for health insurance claims data¹². General practitioner in South Korea currently identify the patients as having AD and taking AAD through EDI. This study investigated the changes in the numbers of deaths and the AADs used to treat AD in the National Health Insurance System (NHIS) of South Korea. With the increasing biomedicalisation of dementia, we have announced that it can treat dementia or slow the disease's progression^{13 14 15 16 17 18}. The prescriptions for AAD have increased dramatically, and now the results need to be examined.

Results

Compared with South Koreans' increased life expectancy, there was a gradual decline in HD patients' life expectancy in 2005–2019. HD patients taking AAD group 2 together with group 1 had a shorter lifespan than those taking AAD group 1 alone (Fig. 1). The mean age of deaths while taking the treatment for dementia symptoms only (AAD group 1) is shown blue in the figure. The mean age of deaths while taking additional psychiatric drugs (AAD group 2) is red. In 2018–2019, the life expectancies of HD patients taking additional psychotropic medications suddenly dropped in Sorokdo National Hospital. This is presumed to be because a public health doctor was working during 2017–2019 in Sorokdo National Hospital to substitute military services to administer AAD group 2 thoroughly.

However, the life expectancies of HD patients taking AAD group 1 (blue) also decreased in Sorokdo National Hospital. On the other hand, the life expectancy of the general Korean population is on the rise. Thus, it can be estimated that AAD group 1 reduces life expectancy.

First-NHIS-Retrieval Results

From 2010 to June 2019, the DMA increased the diagnosis of patients with MCI or AD by 3.26 times and AAD prescription by 4.65 times in South Korea (Fig. 2).

We requested and analysed the entire ICD 9 and 10 code data (from 2010 to 2019) of AAD and deaths from the NHIS with the Open Data Mediation Committee of South Korea according to the Official Information Disclosure Act in South Korea. NHIS provided the information of deaths (Table 1). The number of users who took AAD in Korea increased by 2.16 times, and the number of deaths increased by 2.51 times from 2010 to June 2019 (Fig. 3). This number of AAD and deaths is the baseline.

Table 1
NHIS Dementia Medicines: Users and Deaths Toll.

Year	AAD		Donepezil		Rivastigmine		Memantine		Risperidone		Fluoxetine		Olanzapine	
	User	Death	User	Death	User	Death	user	death	user	death	user	death	user	death
2010	1,496,235	78,528	96,820	12,575	8,070	780	31,965	5,559	181728	8945	156,899	1,802	37,810	1,654
2011	1,624,963	87,053	123,101	15,797	9,788	850	35,315	5,945	186077	8976	151,252	1,580	45,177	2,001
2012	1,793,974	100,711	150,128	19,604	11,218	1,103	37,138	6,419	191121	9519	150,654	1,582	54,344	2,681
2013	1,879,280	109,772	176,440	22,941	11,935	1,170	38,391	6,403	189702	9354	140,194	1,439	59,184	3,112
2014	2,028,410	119,542	204,724	26,636	13,705	1,291	43,165	6,568	190178	9271	134,013	1,395	63,444	3,276
2015	2,191,614	135,524	236,834	32,084	15,542	1,847	52,358	8,134	195951	10052	133,262	1,373	64,123	3,036
2016	2,373,538	148,351	267,241	36,375	15,103	1,682	58,626	9,080	199776	10396	137,846	1,329	66,902	3,368
2017	2,598,416	167,853	294,203	42,187	14,443	1,716	65,605	10,718	203635	10822	144,496	1,268	75,153	3,700
2018	2,880,654	185,099	319,751	47,487	14,777	1,839	70,873	11,597	208994	11179	157,170	1,369	81,868	4,042
2019	3,234,536	197,232	336,683	48,830	14,964	1,840	79,770	12,714	228123	12044	173,284	1,405	87,565	4,359

Table 2
Lee's hidden data and result

Year	AAD		Donepezil		Rivastigmine	Memantine	Risperidone	Fluoxetine				
	User (B-A)	Death (B-A)	User (B-A)	Death (B-A)								
2010	128,728	8,525	26,281	3,222	1,718	70	3,350	386	4349	31	-5,647	-222
2011	169,011	13,658	27,027	3,807	1,430	253	1,823	474	5044	543	-598	2
2012	85,306	9,061	26,312	3,337	717	67	1,253	-16	-1419	-165	-10,460	-143
2013	149,130	9,770	28,284	3,695	1,770	121	4,774	165	476	-83	-6,181	-44
2014	163,204	15,982	32,110	5,448	1,837	556	9,193	1,566	5773	781	-751	-22
2015	181,924	12,827	30,407	4,291	-439	-165	6,268	946	3825	344	4,584	-44
2016	224,878	19,502	26,962	5,812	-660	34	6,979	1,638	3859	426	6,650	-61
2017	282,238	17,246	25,548	5,300	334	123	5,268	879	5359	357	12,674	101
2018	353,882	12,133	16,932	1,343	187	1	8,897	1,117	19129	865	16,114	36
2019	-3,234,536	-197,232	-336,683	-48,830	-14,964	-1,840	-79,770	-12,714	-228123	-12044	-173,284	-1,405
Results of the hidden equation for a comparison graph												
Year	AAD		Donepezil		Rivastigmine	Memantine	Risperidone	Fluoxetine				
2010	0.0662		0.1226		0.0407	0.1152	0.0071	0.0393				
2011	0.0808		0.1409		0.1769	0.2600	0.1077	-0.0033				
2012	0.1062		0.1268		0.0934	-0.0128	0.1163	0.0137				
2013	0.0655		0.1306		0.0684	0.0346	-0.1744	0.0071				
2014	0.0979		0.1697		0.3027	0.1703	0.1353	0.0293				
2015	0.0705		0.1411		0.3759	0.1509	0.0899	-0.0096				
2016	0.0867		0.2156		-0.0515	0.2347	0.1104	-0.0092				
2017	0.0611		0.2075		0.3683	0.1669	0.0666	0.0080				
2018	0.0343		0.0793		0.0053	0.1255	0.0452	0.0022				
2019	0.0610		0.1450		0.1230	0.1594	0.0528	0.0081				

The number of users who took donepezil in Korea increased by 3.48 times, and the number of deaths increased by 3.88 times from 2010 to June 2019. The number of users who took rivastigmine in Korea increased 1.84 times, and the number of deaths increased by 2.36 times from 2010 to June 2019. The number of users who took memantine in Korea increased 2.50 times, and the number of deaths increased by 2.29 times from 2010 to June 2019. The number of users who took risperidone in Korea increased 1.26 times, and the number of deaths increased by 1.35 times from 2010 to June 2019. The number of users who took galantamine and other psychotropic medications in Korea increased 1.55 times, and the number of deaths increased by 1.60 times from 2010 to

June 2019 (Fig. 4). It was significant when comparing death among AAD users. Cholinesterase inhibitors (ChEIs: donepezil, rivastigmine, and galantamine) increase mortality when used to treat dementia.

However, rivastigmine had a significant difference in the increase or decrease in users from 2014 to 2019. Moreover, memantine did not show a considerable increase in the number of deaths than the increase in users. So, we needed a comparison graph for hidden data.

Second-Data-Processing results

We developed an equation to interpret the data for this study. By comparing the rate at which the number of deaths increases when the number of users increases, we can compare deaths caused by dementia medicines.

[Lee's hidden equation for a comparison graph]

X is the year, Y is (death B – death A)/(user B – user A). (1)

If the independent variables are AAD, Donepezil, Rivastigmine, Memantine, Risperidone, Fluoxetine, Olanzapine, Sertraline, Quetiapine, Aripiprazole, Escitalopram, and the others, then the dependent variable is Lee's hidden data by ANOVA Calculator. It makes to calculate the F-ratio value and the p-value by One-Way Repeated Measures ANOVA Calculator (Fig. 5).

The population are all Koreans. The number of deaths is the independent variable. If there are five independent variables (AAD, Donepezil, Rivastigmine, Memantine, Risperidone), the dependent variable is Lee's hidden data. The output of the ANOVA Calculator is pretty significant. The F-ratio value is 3.2028. The p-value is .023868. (The result is significant at $p < .05$.) (Supplement Sect. 3. Statistics Table 19 – 1, One-Way Repeated Measures ANOVA Calculator.)

We used AAD as the reference line. Although rivastigmine was rapidly increased and decreased death rates, it was the drug that increased the death rate according to the trend line (Fig. 6). Memantine did not increase the number of deaths than the increase of users: The number of users increased 2.50 times, and the number of deaths increased by 2.29 times from 2010 to June 2019. However, when the hidden equation was used, memantine also increased the death rate (Fig. 7).

Discussion

This study was conducted from 2005 to 2020 based on the medical records of Sorokdo National Hospital. However, this study was initiated in February 1962 by Sister Marianne Stoeger and Sister Margaritha Pissarek. They left Sorok island on November 21, 2005, returned to their homeland. They stayed for 40 years with exceptional compassion for their patients. However, the average life expectancy of HD patients began to decline overall in the four groups from 2005 after they left (Fig. 8). The life expectancy of HD patients was longer than that of Koreans because of taking dapsone^{6 7 8 9 10}. Even more embarrassing, the group's life expectancy taking AAD (red and black) was higher than that of the group not taking AAD (blue and green), and all four groups tended to decrease. Groups not taking dapsone (green) live longer than groups taking dapsone (blue).

It is estimated to increase smoking and drinking because the HD patients were guaranteed political freedom when the two sisters left¹⁹. It is natural for people with stronger hearts and health to live longer. AD was more prevalent in those who lived longer. After the management of HD patients and AD patients was performed by Korean medical staff, the increase in AAD administration and hospitalisation was the cause of the rapid declining graph. The control group on Sorok Island, created by the two sisters for 40 years, shows that death tolls are more important than life expectancy when studying mortality.

The AD2000 Collaborative Group

The AD2000 Collaborative Group's research already reported the following results in 2004. Donepezil is not cost-effective, with benefits below minimally relevant thresholds²⁰. There were no significant results between donepezil and placebo in adverse events or deaths, formal care costs, unpaid caregiver time, carer psychopathology, behavioural and psychological symptoms. There was also no significant difference between 5 mg and 10 mg donepezil. More effective treatments than cholinesterase inhibitors are needed to treat AD.

ChEIs and memantine do not reduce the progression rate of Alzheimer's disease^{21 22 23 24 25}. AD patients who received ChEIs and memantine took them for longer, were more functionally impaired, and showed more significant cognitive decline than those who only received ChEIs²⁶. When we assess the hazard of death in persons with and without amnesic mild cognitive impairment (MCI), MCI is associated with increased mortality²⁷. They tended to take ChEIs more than without amnesic MCI persons.

The DMA reinforced the socialisation of elder care, and the enduring fear of dependency in old age forced Koreans to cooperate in diagnostic tests and treatments for dementia actively²⁸. It is well understood that individual Koreans are very active in the prevention of SARS-CoV-2²⁹.

Korean Government's Legislative Process and Medical Staff Medication

The Korean government has established national policies for dementia care, and compulsory long-term care insurance for older people was introduced³⁰. The 'War against Dementia' and the First National Dementia Plan was announced in 2008³¹. It facilitates the socialisation of long-term care services at a national level. The DMA was legislated in August 2011. The government announced the DMA as a reform plan, emphasising changes such as increasing coverage and improving the quality of services³⁰. The DMA intended to lighten its burden on society and help enhance national health by establishing and implementing comprehensive policies on preventing dementia, supporting dementia patients, and researching finding a cure for dementia.

As a result of the election in May 2017, the new president announced the National Duty for Dementia³². The proportion of elderly over 65 years exceeded 14% of the entire population in 2018³³, and dementia care became a major national issue. The DMA was strengthened on June 12, 2018. The Korean government installed Community Dementia Reassurance Centers successively at all Community Health Centers to establish a community-based dementia management system according to the National Duty for Dementia. Psychiatrists or neurologists of medical institutions engaged in medical diagnosis and treatment under the Medical Service Act³⁴. They strengthened the dementia management programs that administer AAD to MCI or delirium as a preventive and treatment^{35–39}. They insisted that the 1-year persistence rate of ChEIs for AD patients should be specially monitored to optimise treatment persistence because patients are less likely to remain on therapy than those in other countries³⁶. The no improvement results of clinical studies on AAD were already published in 2005–2009^{21 22 23 24 40 26}. In Korea, medical staff started to publish clinical studies of ChEIs and memantine as significant but modest therapeutic improvement in the year 2009^{35 41 42}.

Furthermore, the media interviewed medical staff on whether the administration of AAD is essential to slow down and treat dementia^{43 44}. By Article 12 (1) of the DMA, the government and local governments provided support for the treatment and diagnosis of dementia in consideration of the economic burden of dementia patients. NHIS began to reduce the cost of AAD drugs for dementia patients, and the drugs became almost free. From 2010 to June 2019, policymakers and medical staff increased the diagnosis of patients with MCI or AD by 3.26 times and AAD prescriptions by 4.65 times in Korea.

The neurological side effects of ChEIs for AD patients

The percentage of new users was 2.5% across hospitalizations for Alzheimer's medication⁴⁵. Neuropsychiatric symptoms and adverse drug reactions were associated with significantly increased prevalence of further psychotropic medication use⁴⁶, and hospital stays due to dementia and the need of care were predictors for new use of psychotropic medication⁴⁷. All studies from many countries have already confirmed that antipsychotic drugs should not be administered to dementia patients because of the risk of seizures and all-cause mortality^{48 49}. Deprescribing psychotropic medications are feasible for most people experiencing no withdrawal symptoms in long-term care^{50 51}. Life expectancy is significantly different between AD and AAD groups 1 and 2 in the Sorokdo National Hospital (Fig. 1. between 2018 and 2019). It is suspected because the patients were hospitalised in the psychiatric ward, but the life expectancy of AAD group 1 is also decreased. Adverse events of ChEIs were reported by 81.2% of 196 participants in the Comparative Research of Alzheimer's Disease Drugs⁵².

The neurological side effects of ChEIs for AD patients are similar to the neurological symptoms of AD patients. Donepezil treated patients had increased disinhibited or compulsive acts, which abated with the discontinuation^{53 54}. Few specialists can distinguish the side effects caused by dementia or donepezil drugs: dizziness, delusions, dream abnormalities, ataxia, convulsive seizures, hemiplegia, hypertonia, and salivation⁵⁵. When connected with the Sorokdo National Hospital's EDI database, we could evaluate AAD prescriptions for fifteen years⁵⁶. Three ChEIs are approved for use in mild to moderate AD, and their symptomatic benefit in AD has been confirmed via meta-analyses assessing both cognitive performance and global functioning⁵⁷. However, the data analysis on the number of people who took four FDA-approved therapeutics (three ChEIs and memantine) and the number of fatalities revealed that the number of deaths increased as the number of prescriptions increased. NHIS did not separately provide the number of users and deaths of galantamine because of the pharmaceutical company's request, but it could be sufficiently estimated. Memantine did not show a significant increase in the number of deaths than the increase in users, but the death toll increased in the hidden equation graph (Fig. 6).

We should re-examine the life expectancy of dementia patients treated by AAD

We re-evaluated the effects of long-term accumulation of four FDA-approved therapeutics. ChEIs' neurological side effects are very similar to AD neurologic symptoms^{53 54,55}. Many unique ethical issues arise when treating AD, and psychiatrists are prone to pharmacological prescriptions for their ease of management of late-stage AD patients⁵⁸. Today, patients with Alzheimer's disease (AD) tend to have more drugs prescribed and much older and frailer than some decades ago. According to the "evidence-based medicine issue", pushing clinical trials to anticipate its detection even before the appearance of its clinical manifestations may overshadow the person's values and priorities⁵⁹. Donepezil, which most patients have taken, increased more patients with neurological abnormalities with heart failure^{54 60}. Patients with neurological abnormalities are classified as severe AD because violence and abnormal behaviour are increased⁵⁵. Clinicians promptly administer the AAD group 2 with restraining the patient, and the number of deaths from AAD group 2 replaces the number of deaths from donepezil like Fig. 1 and Fig. 8. It may explain why the mortality from donepezil relatively seems low when cognitive function is maintained partly by their cognitive effects by ChEIs⁶¹. We watched the report of donepezil initiation associated with better survival benefit than other AD medications (memantine and oral and transdermal forms of rivastigmine) from AD medication groups in a US national sample of Medicare beneficiaries⁶². But in our judgement, the number of patients who caused side effects by donepezil was not recorded as death because they went to the ward to treat evolving neurological symptoms or heart failure. This study elucidates the direct effects of AD medications on mortality in real-world settings.

Many toxins are cholinesterase inhibitors

However, many toxins are cholinesterase inhibitors, and these toxins can cause death if given at high enough dosages. There is no known cumulative effect on AD patients who have taken ChEIs or memantine consistently for long periods. Botulinum toxin blocks the release of acetylcholine hormone from the presynaptic terminal by preventing acetylcholine release⁶³. Black widow spider venom is thought to be associated with a wide release of neurotransmitters, especially norepinephrine and acetylcholine, due to spider envenomation. If widow venom exhausts all acetylcholine supplies as the opposite effect of botulinum toxin, paralysis occurs^{64 65}.

Acetylcholine performs various physiologic functions through cholinergic muscarinic receptors; five different types of muscarinic receptors, M1, M2, M3, M4, and M5. The muscarinic receptor M1 is in the cerebral cortex, salivary glands, and gastric glands. The muscarinic receptor M2 is present in smooth muscle as well as cardiac tissue. The muscarinic receptor M3 is found in smooth muscle cells, particularly of the bronchioles, iris, bladder, and small intestines. The

muscarinic receptors M4 and M5 have a less clear distribution but have been found in the hippocampus, substantia nigra, and other locations within the brain^{66 67}.

The non-neuronal cholinergic systems are involved in the pathophysiology of diseases⁶⁸. The cardiovascular system determines generalised vasodilation, negative chronotropic effects, and negative inotropic effects. It has a less pronounced negative dromotropic effect in the specialised tissue of the sinoatrial and atrioventricular nodes at the ventricular level than other organs. Muscarinic receptor 2 is not the only functional subtype found within the heart, and muscarinic receptors 1 and 3 mediate both dilation and constriction in the vasculature⁶⁹.

When a patient taking dapsone, mainly used in clinical studies on inflammasome competitors^{56 19 70}, stopped it for stroke treatment and administered acetylcholine precursors for dementia care, the patient's courses were rapidly progressed to severe hypertension and neurologic abnormalities⁵⁵.

AADs administered to the elderly are closely related to health insurance policies. If the elderly die early, health insurance companies will benefit. However, health insurance policies have been implemented to improve the health of the elderly⁷¹. Long-term administration of ChEIs to patients with dementia has increased mortality. The effects of ChEIs on cardiovascular systems should be analysed and studied.

Methods

Experimental Design

According to the Official Information Disclosure Act in Korea, the Seoul study analysed AD and anti-Alzheimer's disease drug (AAD) used in Hansen subjects. We searched all medical records of the National Health Insurance Service (NHIS) in Korea when the Korean government computerised the International Classification of Diseases (ICD)-9 (10) code and Electronic Data Interchange (EDI). We also connected the medical record database of the Sorokdo National Hospital and archived it from January 2005 to June 2020. The Sorokdo National Hospital was established and operated exclusively for HD patients. Since HD patients take therapeutics for leprosy, a Seoul cohort runs to study AD and AAD correlations.

With the ICD-9 and -10 codes, medical data on the correlation between AD and AAD were then analysed for cohort correlational possibility. AAD First group, according to Korea Drug Code Medicine, First Group: For symptomatic relief of Alzheimer's disease (donepezil hydrochloride, rivastigmine, galantamine, N-methyl-D-aspartate (NMDA) receptor antagonist). AAD Second group is according to Korea Drug Code Medicine Second Group: For psychologic symptoms of Alzheimer's disease (haloperidol, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Oxcarbazepine, fluvoxamine, Escitalopram, Trazodone, Sertraline, Escitalopram, Fluoxetine). (Supplement 1. Korea Drug Code Medicine) The mean age of death of AD patients was classified into the first or second group.

Through the coordination of the Open Data Mediation Committee, data on the number of deaths among people taking AAD from 2010 to 2019 were available from the NHIS. We analysed the entire ICD 9 and 10 code data (from 2010 to 2019) of AAD and death from NHIS. We used the software programs Object-Relational DBMS and Google spreadsheet for R² analysis and power series calculations. (Supplement 2. DATA)

Code Availability

We used Google spreadsheets for R² calculation and drawing the trend lines.

Data Availability

The authors declare that all primary data generated or analysed during this study supporting the findings are available in the article and supplement files. Additional data that support the findings of this study are available from the corresponding author upon reasonable request. Source data are provided with this paper.

Data And Material Availability

According to the Official Information Disclosure Act in Korea, it is possible to provide public access to a dataset based on the linkage of data from nationwide public registries. Access to the registry data of the National Health Insurance Service (NHIS), the Sorokdo National Hospital, and the Health Insurance Review and Assessment system can be granted to individual researchers only upon seeking approval, according to the National Agency for Data Protection. We therefore cannot place the dataset in a public repository. However, pooling of aggregated data is possible and would be of interest to the research group.

Declarations

Acknowledgements

Sister Marianne Stoeger and Sister Margaritha Pissarek are two Austrian nurses. They attended members of the Catholic Church of Christ Kingdom Ladies' Association did not hesitate to pack their luggage at the local Catholic bishop's words, "We need a nurse to take care of the Hansen people in Sorok Island, Korea." They volunteered to care for patients as part of a 5-year project at a Korean 'leper colony'. After graduating from her nursing school at the University of Innsbruck Nursing School in Tyrol, Western Austria, Marianne, who worked at a hospital in Innsbruck, joined Sorok Island in February 1962. She was 28 years old at the time. Sister Margaritha, her nursing school roommate, entered Sorok Island in October 1967. This study was conducted from 2005 to 2020 based on the medical records of Sorokdo National Hospital. However, the patient research in the report was initiated by Sister Marianne Stoeger and Sister Margaritha Pissarek. Sister Marianne and Sister Margaritha left Sorok island on November 21, 2005, returned to their homeland. They stayed for 40 years and spent their

wages on supplies and their work effectively unpaid. When HD patients were treated with fear, suspicion and cruelty, these two nurses showed exceptional compassion for their patients. So we decided to call this study 'Marianne and Margaritha's deprescribing treatment for human survival'.

This study deals with society's pathology, which we learned about during a long journey to treat a person with Alzheimer's disease, who went to heaven on January 3 this year. This study is published through a branch journal of *Nature*, replacing the person's obituary.

Funding

No funding

Author Contributions

JL designed the study, developed the hidden equation, analyzed the data, and wrote the paper.

Additional Information

Competing Interests

The author(s) declare no competing interests.

References

1. Butlin, C. R. Excess of deaths of leprosy-affected people. *Lepr. Rev.* **91**, 220-223 (2020).
2. Glover, G., Williams, R., Heslop, P., Oyinlola, J. & Grey, J. Mortality in people with intellectual disabilities in England. *J. Intellect. Disabil. Res.* **61**, 62-74 (2017).
3. Walker, S. L., Lebas, E., Doni, S. N., Lockwood, D. N. J. & Lambert, S. M. The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study. *PLoS Negl. Trop. Dis.* **8**, e2690 (2014).
4. Shen, J., Liu, M., Zhou, M. & Li, W. Causes of death among active leprosy patients in China. *Int. J. Dermatol.* **50**, 57-60 (2011).
5. Ferreira, A. F. *et al.* Mortalidade por hanseníase em contextos de alta endemicidade: análise espaço-temporal integrada no Brasil. *Rev. Panam. Salud Pública* **43**, e87 (2019).
6. Cho, Y., Shim, E., Lee, K. S. & Park, S. C. Mortality profiles of leprosy-affected elderly in Korea: a demographic perspective. *Asia-Pac. E-J. Health Soc. Sci.* **3**, pp. 1-5 (2014).
7. Cho, S. C. *et al.* DDS, 4,4'-diaminodiphenylsulfone, extends organismic lifespan. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 19326-19331 (2010).
8. Cho, S. C. *et al.* Protective effect of 4,4'-diaminodiphenylsulfone against paraquat-induced mouse lung injury. *Exp. Mol. Med.* **43**, 525-537 (2011).
9. Park, S. C. Serendipity in search for longevity from experiences of Hansen people. *Transl. Med. Aging* **1**, 12-17 (2017).
10. Choi, H. *et al.* DDS promotes longevity through a microbiome-mediated starvation signal. *Transl. Med. Aging* **3**, 64-69 (2019).
11. Korea Legislation Research Institute. *Dementia management act, act no. 15649, division of dementia policy of the ministry of health and welfare (MOHW)* (Korea Legislation Research Institute, 2018).
12. Hwang, E. J. *et al.* Mapping Korean EDI medical procedure code to SNOMED CT. *Stud. Health Technol. Inform.* **264**, 178-182 (2019).
13. Greenberg, S. M. *et al.* Donepezil therapy in clinical practice: a randomized crossover study. *Arch. Neurol.* **57**, 94-99 (2000).
14. Seltzer, B. *et al.* Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. *Arch. Neurol.* **61**, 1852-1856 (2004).
15. Tariot, P. N. *et al.* Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *JAMA* **291**, 317-324 (2004).
16. Farlow, M. R. & Cummings, J. L. Effective pharmacologic management of Alzheimer's disease. *Am. J. Med.* **120**, 388-397 (2007).
17. Raina, P. *et al.* Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. *Ann. Intern. Med.* **148**, 379-397 (2008).
18. Lu, P. H. *et al.* Donepezil delays progression to AD in MCI subjects with depressive symptoms. *Neurology* **72**, 2115-2121 (2009).
19. Lee, J. H., An, H. K., Sohn, M. G., Kivela, P. & Oh, S. 4,4'-Diaminodiphenyl sulfone (DDS) as an inflammasome competitor. *Int. J. Mol. Sci.* **21**, 5953 (2020).
20. Courtney, C. *et al.* Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. *Lancet (London, England)* **363**, 2105-2115 (2004).
21. Petersen, R. C. *et al.* Vitamin E and donepezil for the treatment of mild cognitive impairment. *N. Engl. J. Med.* **352**, 2379-2388 (2005).
22. Feldman, H. H. *et al.* Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. *Lancet Neurol.* **6**, 501-512 (2007).
23. Raschetti, R., Albanese, E., Vanacore, N. & Maggini, M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. *PLoS Med.* **4**, e338 (2007).
24. Dysken, M. W. *et al.* Effect of vitamin e and memantine on functional decline in alzheimer disease: the TEAM-AD VA cooperative randomized trial. *JAMA* **311**, 33-44 (2014).
25. Winblad, B. *et al.* Safety and efficacy of galantamine in subjects with mild cognitive impairment. *Neurology* **70**, 2024-2035 (2008).

26. Schneider, L. S., Insel, P. S., Weiner, M. W. & Alzheimer's Disease Neuroimaging Initiative. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's disease neuroimaging initiative. *Arch. Neurol.* **68**, 58-66 (2011).
27. Hunderfund, A. *et al.* Mortality in amnesic mild cognitive impairment: a prospective community study. *Neurology* **67**, 1764-1768 (2006).
28. Lee, J. Living with/out dementia in contemporary South Korea. *Med. Anthropol. Q.* **33**, 501-516 (2019).
29. Park, Y. J. *et al.* Contact tracing during coronavirus disease outbreak, South Korea, 2020. *Emerg. Infect. Dis.* **26**, 2465-2468 (2020).
30. Chon, Y. The expansion of the Korean welfare state and its results@ focusing on long term care insurance for the elderly. *Soc. Policy Adm.* **48**, 704-720 (2014).
31. Lee, S. B. The community dementia reassurance center (chime ansim center) in South Korea. *Ann. Geriatr. Med. Res.* **23**, 43-44 (2019).
32. Yonhap News. Gov't to take more responsibility for dementia patients. (Yonhap News Agency, 2017).
33. Nam, H. J., Hwang, S. H., Kim, Y. J. & Kim, K. W. *Korean dementia observatory 2018* (Seoul Central Dementia Center, Ministry of Health and Welfare, 2018).
34. Youn, H. & Jeong, H. G. Pharmacotherapy for dementia. *J. Korean Med. Assoc.* **61**, 758-764 (2018).
35. Lee, D. W., Huh, Y. S. & Kim, K. W. Evidence-based treatment of Alzheimer's disease. *J. Korean Med. Assoc.* **52**, 417-425 (2009).
36. Ahn, S. H. *et al.* Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea. *Arch. Pharmacol. Res.* **38**, 1255-1262 (2015).
37. Lee, K. U. *et al.* The effect of choline acetyltransferase genotype on donepezil treatment response in patients with Alzheimer's disease. *Clin. Psychopharmacol. Neurosci.* **13**, 168-173 (2015).
38. Hong, Y. J. *et al.* Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer's disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial. *Alzheimer's Res. Ther.* **11**, 37 (2019).
39. Lee, S. J., Seo, H. J., Lee, D. Y. & Moon, S. H. Effects of a dementia screening program on healthcare utilization in South Korea: a difference-in-difference analysis. *Int. J. Environ. Res. Public Health* **16**, 3837 (2019).
40. Kang, H. S. *et al.* Comparative assessment of clinical efficacy between the naive and the switching group to donepezil: 12 months prospective study. *J. Korean Geriatr. Psychiatry* **14**, 111-117 (2010).
41. Kang, H. S. *et al.* Effects of galantamine treatment on attention, activities of daily living, and neuropsychiatric symptoms between the patients with pure Alzheimer's disease and mixed dementia. *J. Korean Geriatr. Psychiatry* **16**, 24-30 (2012).
42. Yu, K. H. *Taking the fight to Alzheimer's disease* (Korea JoongAng Daily in association with the New York Times, 2011).
43. Lee, D. Y. [Editor Kim Nam-Jung goes] Patients who haven't used dementia medicine, 90% of them are severe after 8 years... What if? (JoongAng Ilbo, 2018).
44. Möllers, T. *et al.* New use of psychotropic medication after hospitalization among people with dementia. *Int. J. Geriatr. Psychiatry* **35**, 640-649 (2020).
45. Stingl, J. *et al.* Prevalence of psychotropic drugs in cases of severe adverse drug reactions leading to unplanned emergency visits in general hospitals. *Pharmacopsychiatry* **53**, 133 (2020).
46. Jordan, S. *et al.* Nurse-led medicines' monitoring in care homes, implementing the Adverse Drug Reaction (ADRe) Profile improvement initiative for mental health medicines: An observational and interview study. *PLoS One* **14**, e0220885 (2019).
47. Stone, M. *Mortality and antipsychotic drug use in dementia-related behavioral disorders.* US Department of Health and Human Services (Food and Drug Administration, Center for Drug Evaluation and Research, 2005).
48. Du, Y., Wolf, I. K., Busch, M. A. & Knopf, H. Associations between the use of specific psychotropic drugs and all-cause mortality among older adults in Germany: Results of the mortality follow-up of the German National Health Interview and Examination Survey 1998. *PLoS One* **14**, e0210695 (2019).
49. Ralph, S. J. & Espinet, A. J. Increased all-cause mortality by antipsychotic drugs: updated review and meta-analysis in dementia and general mental health care. *J. Alzheimers Dis Rep* **2**, 1-26 (2018).
50. Dharmarajan, T. S. *et al.* Deprescribing as a clinical improvement focus. *J. Am. Med. Dir. Assoc.* **21**, 355-360 (2020).
51. Campbell, N. L. *et al.* Adherence and tolerability of Alzheimer's disease medications: a pragmatic randomized trial. *J. Am. Geriatr. Soc.* **65**, 1497-1504 (2017).
52. Mendez, M. F., Shapira, J. S., McMurtry, A. & Licht, E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. *Am. J. Geriatr. Psychiatry* **15**, 84-87 (2007).
53. Lee, J. H., Choi, S. H., Lee, C. J. & Oh, S. S. Recovery of dementia syndrome following treatment of brain inflammation. *Dement. Geriatr. Cogn. Disord. Extra* **10**, 1-12 (2020).
54. Lee, J. H., Lee, C. J., Park, J. & Lee, S. J. *The neuro-inflammasome in Alzheimer's disease and cerebral stroke.* <https://osf.io/y2ugc/> (2021).
55. Lee, J. H. *et al.* The preventive and treatment of the neuro-inflammasome in Sorokdo national hospital. *Sci. Rep.*; <https://doi.org/10.21203/rs.3.rs-243831/v1> (2021).
56. Birks, J. S. Cholinesterase inhibitors for Alzheimer's disease. *Cochrane Database Syst. Rev.*, CD005593; <https://doi.org/10.1002/14651858.CD005593> (2006).
57. Howe, E. G. Ethical issues in diagnosing and treating Alzheimer disease. *Psychiatry (Edgmont (Pa. : Township))* **3**, 43-53 (2006).
58. Canevelli, M., Vanacore, N., Blasimme, A., Bruno, G. & Cesari, M. Overtreating Alzheimer's disease. *J. Prev. Alzheimer's Dis.* **8**, 234-236 (2021).
59. Kho, J. *et al.* Long term use of donepezil and QTc prolongation. *Clin. Toxicol. (Phila)* **59**, 208-214 (2021).

60. Xu, H. *et al.* Long term effects of cholinesterase inhibitors on cognitive decline and mortality. *Neurology*, <https://doi.org/10.1212/wnl.0000000000011832> (2021).
61. Bhattacharjee, S. *et al.* Alzheimer's disease medication and risk of all-cause mortality and all-cause hospitalization: A retrospective cohort study. *Alzheimers Dement. Transl. Res. Clin. Interv.* **5**, 294-302 (2019).
62. Huang, W., Foster, J. A. & Rogachefsky, A. S. Pharmacology of botulinum toxin. *J. Am. Acad. Dermatol.* **43**, 249-259 (2000).
63. Tzeng, M. C., Cohen, R. S. & Siekevitz, P. Release of neurotransmitters and depletion of synaptic vesicles in cerebral cortex slices by alpha-latrotoxin from black widow spider venom. *Proc. Natl. Acad. Sci. U. S. A.* **75**, 4016-4020 (1978).
64. Yan, S. & Wang, X. Recent advances in research on widow spider venoms and toxins. *Toxins* **7**, 5055-5067 (2015).
65. Birdsall, N. J. *et al.* Muscarinic receptor subtypes and the selectivity of agonists and antagonists. *Pharmacology* **37 Suppl 1**, 22-31 (1988).
66. Lebois, E. P., Thorn, C., Edgerton, J. R., Popiolek, M. & Xi, S. Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease. *Neuropharmacology* **136**, 362-373 (2018).
67. Wessler, I. & Kirkpatrick, C. J. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. *Br. J. Pharmacol.* **154**, 1558-1571 (2008).
68. Saternos, H. C. *et al.* Distribution and function of the muscarinic receptor subtypes in the cardiovascular system. *Physiol. Genom.* **50**, 1-9 (2018).
69. Lee, J. H. *et al.* The method and results of a treatment targeting SARS-CoV-2-activated inflammasomes. *Nat. Commun.*; <https://doi.org/10.31219/osf.io/jq5tc> (2020).
70. Lee, J. H. *Commentary for the elderly in the pandemic era* (Karger, 2021).

Figures

The life expectancy of Hansen's disease patients of Sorok island




Figure 1

The life expectancy of Hansen's disease patients with Alzheimer's disease at Sorokdo National Hospital. In the group of patients diagnosed with Alzheimer's disease, the mean age of deaths while taking only dementia symptom treatment was blue. The mean age of deaths with taking additional psychiatric drugs is red. In 2018–2019, the life expectancies of HD patients taking additional psychotropic medications were suddenly decreased in the Sorokdo National Hospital. On the other hand, Korean's life expectancy is on the rise (see yellow). The life expectancies of HD patients taking the AAD first group (blue) were decreased in the Sorokdo National Hospital.




Figure 2

Numbers of drug prescriptions for dementia patients in Korea from 2010 to 2019. The state or local government subsidises dementia patients for expenses incurred in the treatment and diagnosis of dementia from its budget, considering each dementia patient's capability to bear such costs. The AD and AAD data were reported from the Health Insurance Review & Assessment system. From 2010 to June 2020, the diagnosis and prescription of patients with MCI and AD in Korea increased 3.26 times and 4.65 times, respectively.




Figure 3

Graph with AAD users and deaths in Korea from 2010 to 2019. The number of users who took AAD in Korea increased 2.16 times, and the number of deaths increased by 2.51 times from 2010 to June 2019. The life expectancy between AD and AAD was significantly observed between 2017 and 2019. It is because the DMA was strengthened on June 12, 2018.




Figure 4

Graph of AAD users and deaths in Korea from 2010 to 2019. The DMA was strengthened on June 12, 2018. The number of users who took donepezil in Korea increased 3.48 times, and the number of deaths increased 3.88 times from 2010 to June 2019. Donepezil users' life expectancies were significantly observed between 2017 and 2019 (Supplementary Fig. S2-1. Graph of donepezil users and deaths in Korea from 2010 to 2019.) The number of users who took rivastigmine in Korea increased 1.85 times, and the number of deaths increased 2.36 times from 2010 to June 2019. The number of users who took memantine in Korea increased 2.50 times, and the number of deaths increased by 2.29 times from 2010 to June 2019. It is prescribed to treat moderate-to-severe AD. The number of users who took risperidone in Korea increased 1.26 times, and the number of deaths increased by 1.35 times from 2010 to June 2019. Risperidone is an antipsychotic medication prescribed to treat schizophrenia and bipolar disorder. The number of users who took galantamine and other psychotropic medications in Korea increased 1.55 times, and the number of deaths increased by 1.60 times from 2010 to June 2019.




Figure 5

Lee's hidden equation graph with AAD users and deaths in Korea from 2010 to 2019. The number of deaths is the independent variable. Lee's hidden equation follows. X is the year, Y is $(\text{death } B - \text{death } A) / (\text{user } B - \text{user } A)$. By comparing the rate at which the number of deaths increases when the number of users increases, we can compare deaths caused by dementia medicines. The population is all Koreans. If the independent variables are AAD, donepezil, rivastigmine, memantine, risperidone, fluoxetine, olanzapine, sertraline, quetiapine, aripiprazole, escitalopram, and others, the dependent variable is Lee's hidden data. It allows us to calculate the F-ratio value and the p-value by the one-way repeated measures ANOVA calculator.




Figure 6

Lee's hidden equation graph with rivastigmine users and deaths in Korea from 2010 to 2019. The number of users who took rivastigmine in Korea increased 1.84 times, and the number of deaths increased by 2.36 times from 2010 to June 2019. The number of users who took AAD in Korea increased 2.16 times, and the number of deaths increased by 2.51 times from 2010 to June 2019. The rivastigmine trend line is black. The trend line of AAD, the reference line, is blue. The pattern of change for rivastigmine is jagged in the hidden equation graph, but the death toll keeps increasing.




Figure 7

Lee's hidden equation graph with memantine users and deaths in Korea from 2010 to 2019. The number of users who took memantine in Korea increased 2.50 times, and the number of deaths increased by 2.29 times from 2010 to June 2019. Memantine is an uncompetitive NMDA receptor modulator. It is prescribed to treat moderate-to-severe AD. The number of users who took AAD in Korea increased 2.16 times, and the number of deaths increased by 2.51 times from 2010 to June 2019. The memantine trend line is black. The trend line of AAD, the reference line, is blue. Memantine did not significantly increase the number of deaths compared to the increase in users, but the death toll increases in the hidden equation graph.




Figure 8

The life expectancy of the four groups of Hansen's disease patients at Sorokdo National Hospital We searched all medical records of the Sorokdo National Hospital when the International Classification of Diseases (ICD)-9 code and Electronic Data Interchange (EDI) were computerized by medical staff. We analysed medical data on the correlation between AAD 1, 2 groups and AD with the ICD-9 and -10 codes. 1.AD group with AAD 1 (+) and AAD 2 (-): In the group of patients diagnosed with Alzheimer's disease, the mean age of deaths while taking only dementia symptom treatment was red. 2.AD group with AAD 1 (+) and AAD 2 (+): In the group of patients diagnosed with Alzheimer's disease, the mean age of deaths while taking dementia symptom treatment and psychotropic medications was black. 3.AD free group with DDS (+): In patients free of Alzheimer's disease, the mean age of deaths while taking dapsone was blue. 4.AD free group with DDS (-): In patients free of Alzheimer's disease, the mean age of deaths while not taking dapsone was green.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryMaterialsDementiaManagementActandDeathToll20210415formatted.docx](#)